Nitto Published siRNA Chemical Optimization Research in Nucleic Acid Therapeutics, Advancing Design Strategies for More Durable LNPーMediated Gene Silencing
Nucleic Acid Ther. 2026 Jul 21: 21593337261469503
Nitto’s publication in Nucleic Acid Therapeutics highlights the importance of chemical modifications for enhanced efficacy and durability of siRNA therapeutics; “Optimized Chemical Modifications Enhance Lipid Nanoparticle-Mediated siRNA Silencing of YAP1 and WWTR1”.
The paper reports that optimized chemical modification patterns can significantly enhance the efficacy and durability of LNP-delivered siRNA targeting YAP1 and WWTR1. Notably, fully modified siRNAs with high 2′-O-methyl (2′-OMe) and 2′-fluoro content (up to 86% 2′-OMe) demonstrated superior in vivo silencing compared with conventional LNP-siRNA designs.
The findings provide practical design insights for next-generation RNAi therapeutics enabled by lipid nanoparticle delivery.
Related publications:
A Novel Bispecific siRNA Concept: Efficient Dual Knockdown of YAP1 and WWTR1 with a Single Guide Strand
https://doi.org/10.1016/j.omtn.2025.102768
